Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis.

A Single-centre, Open-label, Exploratory Study to Investigate the Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05258877

Enrollment

Registered

2022-02-28

Start date

2022-06-10

Completion date

2023-09-30

Last updated

2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis, Pulmonary

Brief summary

To determine the pharmacokinetics of ethionamide (Eto) and ethionamide-sulfoxide (Eto-SO) in participants with tuberculosis (TB) when Eto is dosed under programmatic conditions.

Detailed description

A single-centre, open-label, exploratory pharmacokinetic study. This study is designed to collect blood samples from participants established on a TB treatment regimen which includes Eto. These samples will be analysed for concentrations of Eto and its metabolite Eto-SO. The medication will not be provided by the study, participants will receive their standard of care medication from their local clinic. Participants will continue to take their total daily dose of Eto on study as prescribed by their primary caregiver, this will not change for their participation on study.

Interventions

OTHERPlasma samples

Up to 80ml of plasma may be collected from each participant over the 24 hour sampling period to be used for PK analysis.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Inclusion criteria

* Provide written, informed consent prior to all trial-related procedures. * Male or female, aged between 18 and 65 years, inclusive. * Receiving Eto as a component of a treatment regimen for tuberculosis for at least one month at the time of enrolment. * Ability and willingness of participant or legally authorized representative to provide informed consent.

Exclusion criteria

* Evidence of clinically significant conditions or findings, other than TB, that might compromise safety of the participant or the interpretation of trial endpoints, per discretion of the Investigator. * Receiving prohibited concomitant medications (see Prior and Concomitant Medications) * Evidence of illicit substance use (cannabis, methamphetamines, opiates) * Pregnant or breastfeeding or planning to become pregnant during the study period. * Laboratory values: participants with the following laboratory values at screening * creatinine \>1.5 times upper limit of normal \[ULN\]; * haemoglobin \<8.5 g/dL; * Alanine aminotransferase (ALT) ≥2.0 x ULN;

Design outcomes

Primary

Measure	Time frame	Description
To determine the AUC of ethionamide in participants with tuberculosis (TB) when ethionamide is dosed under programmatic conditions.	2 days	area under the plasma drug concentration versus time (AUC0-24)
To determine the Cmax of ethionamide in participants with tuberculosis (TB) when ethionamide is dosed under programmatic conditions.	2 days	maximum observed plasma drug concentration (Cmax)
To determine the Cmax of ethionamide-sulfoxide in participants with tuberculosis (TB) when ethionamide is dosed under programmatic conditions.	2 days	maximum observed plasma drug concentration (Cmax)
To determine the AUC of ethionamide-sulfoxide in participants with tuberculosis (TB) when ethionamide is dosed under programmatic conditions.	2 days	area under the plasma drug concentration versus time (AUC0-24)

Countries

South Africa

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026